Gachet Benoit, Jouvray Mathieu, Koether Vincent, Collet Aurore, Morell-Dubois Sandrine, Sanges Sébastien, Sobanski Vincent, Hachulla Eric, Launay David
CHU Lille, Department of Internal Medicine and Clinical Immunology, Lille, France.
Department of Biostatistics, ULR 2694 METRICS Evaluation des technologies de santé et des pratiques médicales, CH de Tourcoing, University of Lille, Lille, France.
J Scleroderma Relat Disord. 2024 Oct;9(3):203-209. doi: 10.1177/23971983241238921. Epub 2024 Mar 26.
Anemia is considered a risk factor of severity in systemic sclerosis. Yet, limited data are available on the frequency and causes of anemia in systemic sclerosis. The objectives of our study were to determine the frequency and causes of anemia in systemic sclerosis, to analyze the clinical and biological characteristics of patients with anemia, and to assess the association between anemia and systemic sclerosis prognosis.
We conducted a prospective single-center study from January 2017 to May 2022. Patients underwent a hemoglobin assay and a standardized etiological workup to determine the causes of anemia at the initial visit. Clinical and biological parameters were compared between patients with anemia and those with normal hemoglobin levels. We followed up patients until May 2023 and compared their survival.
A total of 502 systemic sclerosis patients, including 107 diffuse cutaneous systemic sclerosis, were included. At enrollment, 100 patients had anemia. The primary cause of anemia was iron deficiency (40%). Among the 32 patients with iron deficiency-associated anemia who underwent gastrointestinal exploration, 56% had digestive bleeding, with upper gastrointestinal tract involvement being the main cause (90%). Patients with anemia at enrollment had higher systemic sclerosis severity scores and more gastrointestinal symptoms compared to patients without anemia (p < 0.05). They exhibited higher systolic pulmonary artery pressure, lower anemia-corrected diffusing capacity for carbon monoxide, and lower forced vital capacity (p < 0.05). During follow-up, 65 patients (14.8%) died. After adjusting for age, systemic sclerosis subtypes, forced vital capacity, and pulmonary arterial hypertension, anemia at inclusion was associated with a higher mortality rate (hazard ratio: 1.94 (95% confidence interval: 1.39-2.48), p = 0.02).
Our study shows a high frequency of anemia among patients with systemic sclerosis. Most anemias are due to iron deficiency, and gastrointestinal exploration can identify bleeding in the majority of the cases. In addition, our study confirms that systemic sclerosis patients with anemia have a more severe disease and a higher mortality rate.
贫血被认为是系统性硬化症病情严重程度的一个危险因素。然而,关于系统性硬化症贫血的发生率和病因的数据有限。我们研究的目的是确定系统性硬化症贫血的发生率和病因,分析贫血患者的临床和生物学特征,并评估贫血与系统性硬化症预后之间的关联。
我们在2017年1月至2022年5月期间进行了一项前瞻性单中心研究。患者在初次就诊时接受血红蛋白检测和标准化的病因检查以确定贫血的原因。比较贫血患者和血红蛋白水平正常患者的临床和生物学参数。我们对患者进行随访至2023年5月并比较他们的生存率。
共纳入502例系统性硬化症患者,其中包括107例弥漫性皮肤系统性硬化症患者。入组时,100例患者患有贫血。贫血的主要原因是缺铁(40%)。在32例接受胃肠道检查的缺铁性贫血患者中,56%有消化道出血,以上消化道受累为主要原因(90%)。与无贫血患者相比,入组时贫血患者的系统性硬化症严重程度评分更高,胃肠道症状更多(p < 0.05)。他们表现出更高的收缩期肺动脉压、更低的贫血校正一氧化碳弥散量和更低的用力肺活量(p < 0.05)。随访期间,65例患者(14.8%)死亡。在调整年龄、系统性硬化症亚型、用力肺活量和肺动脉高压后,入组时的贫血与更高的死亡率相关(风险比:1.94(95%置信区间:1.39 - 2.48),p = 0.02)。
我们的研究表明系统性硬化症患者中贫血的发生率很高。大多数贫血是由于缺铁,胃肠道检查可在大多数病例中发现出血。此外,我们的研究证实患有贫血的系统性硬化症患者病情更严重,死亡率更高。